{{Rsnum
|rsid=7664751
|Chromosome=4
|position=33728311
|Orientation=plus
|GMAF=0.2658
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 1.8 | 19.5 | 78.8
| HCB | 10.9 | 38.0 | 51.1
| JPT | 9.7 | 44.2 | 46.0
| YRI | 27.9 | 44.9 | 27.2
| ASW | 8.8 | 43.9 | 47.4
| CHB | 10.9 | 38.0 | 51.1
| CHD | 10.1 | 40.4 | 49.5
| GIH | 4.0 | 25.7 | 70.3
| LWK | 22.7 | 47.3 | 30.0
| MEX | 1.7 | 36.2 | 62.1
| MKK | 16.1 | 47.1 | 36.8
| TSI | 2.0 | 16.8 | 81.2
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7664751
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.15, combined P value= 1.76E-04. It is also associated with etoposide clearance.
|Drugs=etoposide
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470204
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7664751
|overall_frequency_n=33
|overall_frequency_d=126
|overall_frequency=0.261905
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=29
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}